You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

19 Results
Guidelines and Advice
Mar 2025
Guidelines and Advice
Status: Current
Mar 2025
Drug
Other Name(s): Sylvant®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Tagrisso®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
siltuximab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC), based on criteria
Exceptional Access Program
    osimertinib - For the treatment of locally advanced, unresectable (stage III) non-squamous non-small cell lung cancer (NSCLC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Drug
Other Name(s): Lynparza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Sacituzumab Govitecan - HR-positive HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
sacituzumab govitecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Drug
Other Name(s): Trodelvy®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025

Pages